What's on this Page
Naftifine Brand Names- Naftin | Naftin-MP
What is Naftifine
Naftifine is a topical antifungal agent for interdigital tinea pedis, tinea cruris, and tinea corporis; limited efficacy has been shown for the treatment of onychomycosis.
It is the first of the allylamine class of antifungals. Unlike the azoles, the allylamines exhibit fungicidal activity at low doses and have the potential for a faster onset of action. In general, however, efficacy and adverse event profiles are similar to the topical azoles.
Naftifine is available as a 1% and 2% cream, and a 1% and 2% gel. The 1% gel and the cream formulations are approved for treatment of tinea pedis, tinea cruris, and tinea corporis; the 2% gel is only approved for treatment of interdigital tinea pedis.
The antifungal spectrum of activity includes: Trichophyton rubrum (all formulations), Trichophyton mentagrophytes (1% cream, 1% and 2% gel), Epidermophyton floccosum (1% cream, 1% and 2% gel), and Trichophyton tonsurans (1% gel).
The cream has been shown to be equivalent in efficacy to clotrimazole 1% cream, miconazole 1% cream, econazole 1% cream, tolnaftate, and topical terbinafine in the treatment of dermatophytes.
Naftifine was approved by the FDA in 1988.
Indications
- Aspergillus flavus
- Aspergillus fumigatus
- Candida albicans
- Candida sp.
- Epidermophyton floccosum
- Microsporum audouinii
- Microsporum canis
- Microsporum gypseum
- onychomycosis
- Sporothrix schenckii
- tinea corporis
- tinea cruris
- tinea pedis
- Trichophyton mentagrophytes
- Trichophyton rubrum
- Trichophyton tonsurans
- Trichophyton verrucosum
Side Effects
- agranulocytosis
- contact dermatitis
- dizziness
- erythema
- headache
- leukopenia
- pruritus
- rash
- skin irritation
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- accidental exposure
- breast-feeding
- children
- infants
- neonates
- occlusive dressing
- ocular exposure
- pregnancy
Interactions
There are no drug interactions associated with Naftifine products.
